Global Influenza Vaccines Market Research Report 2019

2 Global Influenza Vaccines Quarterly Market Size Analysis

• 2.1 Influenza Vaccines Business Impact Assessment - COVID-19
  • 2.1.1 Global Influenza Vaccines Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
  • 2.1.2 Global Influenza Vaccines Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Influenza Vaccines Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 Global Influenza Vaccines Quarterly Market Size by Manufacturers, 2019 VS 2020
• 3.2 Global Influenza Vaccines Factory Price by Manufacturers
• 3.3 Location of Key Manufacturers Influenza Vaccines Manufacturing Factories and Area Served
• 3.4 Date of Key Manufacturers Enter into Influenza Vaccines Market
• 3.5 Key Manufacturers Influenza Vaccines Product Offered
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Influenza Vaccines Segments, By Type

• 4.1 Introduction
  • 1.4.1 Trivalent Flu Vaccines
  • 1.4.2 Quadrivalent Flu Vaccines
• 4.2 By Type, Global Influenza Vaccines Market Size, 2019-2021
  • 4.2.1 By Type, Global Influenza Vaccines Market Size by Type, 2020-2021
  • 4.2.2 By Type, Global Influenza Vaccines Price, 2020-2021

5 Impact of Covid-19 on Influenza Vaccines Segments, By Application

• 5.1 Overview
  • 5.5.1 Adults
  • 5.5.2 Pediatrics
• 5.2 By Application, Global Influenza Vaccines Market Size, 2019-2021
  • 5.2.1 By Application, Global Influenza Vaccines Market Size by Application, 2019-2021
  • 5.2.2 By Application, Global Influenza Vaccines Price, 2020-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 AstraZeneca
  • 7.1.1 AstraZeneca Business Overview
  • 7.1.2 AstraZeneca Influenza Vaccines Quarterly Production and Revenue, 2020
  • 7.1.3 AstraZeneca Influenza Vaccines Product Introduction
  • 7.1.4 AstraZeneca Response to COVID-19 and Related Developments
• 7.2 CSL
  • 7.2.1 CSL Business Overview
  • 7.2.2 CSL Influenza Vaccines Quarterly Production and Revenue, 2020
  • 7.2.3 CSL Influenza Vaccines Product Introduction
  • 7.2.4 CSL Response to COVID-19 and Related Developments
• 7.3 GlaxoSmithKline
  • 7.3.1 GlaxoSmithKline Business Overview
  • 7.3.2 GlaxoSmithKline Influenza Vaccines Quarterly Production and Revenue, 2020
  • 7.3.3 GlaxoSmithKline Influenza Vaccines Product Introduction
  • 7.3.4 GlaxoSmithKline Response to COVID-19 and Related Developments
• 7.4 Sanofi
  • 7.4.1 Sanofi Business Overview
  • 7.4.2 Sanofi Influenza Vaccines Quarterly Production and Revenue, 2020
  • 7.4.3 Sanofi Influenza Vaccines Product Introduction
  • 7.4.4 Sanofi Response to COVID-19 and Related Developments
• 7.5 Altimmune
  • 7.5.1 Altimmune Business Overview
  • 7.5.2 Altimmune Influenza Vaccines Quarterly Production and Revenue, 2020
  • 7.5.3 Altimmune Influenza Vaccines Product Introduction
  • 7.5.4 Altimmune Response to COVID-19 and Related Developments
• 7.6 BionVax
  • 7.6.1 BionVax Business Overview
  • 7.6.2 BionVax Influenza Vaccines Quarterly Production and Revenue, 2020
  • 7.6.3 BionVax Influenza Vaccines Product Introduction
  • 7.6.4 BionVax Response to COVID-19 and Related Developments
• 7.7 FluGen
  • 7.7.1 FluGen Business Overview
  • 7.7.2 FluGen Influenza Vaccines Quarterly Production and Revenue, 2020
  • 7.7.3 FluGen Influenza Vaccines Product Introduction
  • 7.7.4 FluGen Response to COVID-19 and Related Developments
• 7.8 FOLIA BIOTECH
  • 7.8.1 FOLIA BIOTECH Business Overview
  • 7.8.2 FOLIA BIOTECH Influenza Vaccines Quarterly Production and Revenue, 2020
  • 7.8.3 FOLIA BIOTECH Influenza Vaccines Product Introduction
  • 7.8.4 FOLIA BIOTECH Response to COVID-19 and Related Developments
• 7.9 Genentech
  • 7.9.1 Genentech Business Overview
  • 7.9.2 Genentech Influenza Vaccines Quarterly Production and Revenue, 2020
  • 7.9.3 Genentech Influenza Vaccines Product Introduction
  • 7.9.4 Genentech Response to COVID-19 and Related Developments
• 7.10 Green Cross
  • 7.10.1 Green Cross Business Overview
  • 7.10.2 Green Cross Influenza Vaccines Quarterly Production and Revenue, 2020
  • 7.10.3 Green Cross Influenza Vaccines Product Introduction
  • 7.10.4 Green Cross Response to COVID-19 and Related Developments
• 7.11 Medicago
  • 7.11.1 Medicago Business Overview
  • 7.11.2 Medicago Influenza Vaccines Quarterly Production and Revenue, 2020
  • 7.11.3 Medicago Influenza Vaccines Product Introduction
  • 7.11.4 Medicago Response to COVID-19 and Related Developments
• 7.12 Moderna Therapeutics
  • 7.12.1 Moderna Therapeutics Business Overview
  • 7.12.2 Moderna Therapeutics Influenza Vaccines Quarterly Production and Revenue, 2020
  • 7.12.3 Moderna Therapeutics Influenza Vaccines Product Introduction
  • 7.12.4 Moderna Therapeutics Response to COVID-19 and Related Developments
• 7.13 Novavax
  • 7.13.1 Novavax Business Overview
  • 7.13.2 Novavax Influenza Vaccines Quarterly Production and Revenue, 2020
  • 7.13.3 Novavax Influenza Vaccines Product Introduction
  • 7.13.4 Novavax Response to COVID-19 and Related Developments
• 7.14 Shijiazhuang Yiling Pharmaceutical
  • 7.14.1 Shijiazhuang Yiling Pharmaceutical Business Overview
  • 7.14.2 Shijiazhuang Yiling Pharmaceutical Influenza Vaccines Quarterly Production and Revenue, 2020
  • 7.14.3 Shijiazhuang Yiling Pharmaceutical Influenza Vaccines Product Introduction
  • 7.14.4 Shijiazhuang Yiling Pharmaceutical Response to COVID-19 and Related Developments
• 7.15 SK Chemicals
  • 7.15.1 SK Chemicals Business Overview
  • 7.15.2 SK Chemicals Influenza Vaccines Quarterly Production and Revenue, 2020
  • 7.15.3 SK Chemicals Influenza Vaccines Product Introduction
  • 7.15.4 SK Chemicals Response to COVID-19 and Related Developments
• 7.16 UNM Pharma
  • 7.16.1 UNM Pharma Business Overview
  • 7.16.2 UNM Pharma Influenza Vaccines Quarterly Production and Revenue, 2020
  • 7.16.3 UNM Pharma Influenza Vaccines Product Introduction
  • 7.16.4 UNM Pharma Response to COVID-19 and Related Developments
• 7.17 Vaccitech
  • 7.17.1 Vaccitech Business Overview
  • 7.17.2 Vaccitech Influenza Vaccines Quarterly Production and Revenue, 2020
  • 7.17.3 Vaccitech Influenza Vaccines Product Introduction
  • 7.17.4 Vaccitech Response to COVID-19 and Related Developments
• 7.18 Vaxart
  • 7.18.1 Vaxart Business Overview
  • 7.18.2 Vaxart Influenza Vaccines Quarterly Production and Revenue, 2020
  • 7.18.3 Vaxart Influenza Vaccines Product Introduction
  • 7.18.4 Vaxart Response to COVID-19 and Related Developments
• 7.19 Vaxine Pty
  • 7.19.1 Vaxine Pty Business Overview
  • 7.19.2 Vaxine Pty Influenza Vaccines Quarterly Production and Revenue, 2020
  • 7.19.3 Vaxine Pty Influenza Vaccines Product Introduction
  • 7.19.4 Vaxine Pty Response to COVID-19 and Related Developments
• 7.20 Visterra
  • 7.20.1 Visterra Business Overview
  • 7.20.2 Visterra Influenza Vaccines Quarterly Production and Revenue, 2020
  • 7.20.3 Visterra Influenza Vaccines Product Introduction
  • 7.20.4 Visterra Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis

• 8.1 Influenza Vaccines Supply Chain Analysis
  • 8.1.1 Influenza Vaccines Supply Chain Analysis
  • 8.1.2 Covid-19 Impact on Influenza Vaccines Supply Chain
• 8.2 Distribution Channels Analysis
  • 8.2.1 Influenza Vaccines Distribution Channels
  • 8.2.2 Covid-19 Impact on Influenza Vaccines Distribution Channels
  • 8.2.3 Influenza Vaccines Distributors
• 8.3 Influenza Vaccines Customers

9 Key Findings

10 Appendix

• 10.1 About Us